| Literature DB >> 34939101 |
Maryse D Berkhout1, Caroline M Plugge1, Clara Belzer1.
Abstract
The intestinal epithelium is protected from direct contact with gut microbes by a mucus layer. This mucus layer consists of secreted mucin glycoproteins. The outer mucus layer in the large intestine forms a niche that attracts specific gut microbiota members of which several gut commensals can degrade mucin. Mucin glycan degradation is a complex process that requires a broad range of glycan degrading enzymes, as mucin glycans are intricate and diverse molecules. Consequently, it is hypothesized that microbial mucin breakdown requires concerted action of various enzymes in a network of multiple resident microbes in the gut mucosa. This review investigates the evolutionary relationships of microbial carbohydrate-active enzymes that are potentially involved in mucin glycan degradation and focuses on the role that microbial enzymes play in the degradation of gut mucin glycans in microbial cross-feeding and syntrophic interactions.Entities:
Keywords: CAZymes; glycosidases; gut microbiota; mucin; syntrophic interactions
Mesh:
Substances:
Year: 2022 PMID: 34939101 PMCID: PMC8966484 DOI: 10.1093/glycob/cwab105
Source DB: PubMed Journal: Glycobiology ISSN: 0959-6658 Impact factor: 4.313
Fig. 1The predominant mucin glycan core structures found in the human gut and a hypothetical mucin glycan. (A) The bottle brush-like structure of a mucin glycoprotein: A secreted MUC2 mucin consists of a protein core (red) and branched, complex glycan extensions (blue). (B) The host intestinal epithelial cells secrete mucin glycans that form a mucus layer to avoid direct contact with bacteria. The mucus consists of an inner layer, which is virtually impenetrable to bacteria, and an outer layer, which forms a niche for specific microbiota. (C) The predominant core structures in the gut. Core 1 consists of galactose that is β1–3-linked to GalNAc. Core 2 contains an additional GlcNAc that is β1–6-linked to GalNAc. Core 3 consists of GlcNAc β1–3 linked to GalNAc. Core 3 can subsequently be extended to core 4 through the β1–6 linkage of another GlcNAc to the GalNAc. (D) A hypothetical mucin glycan that consists of core 2, is extended by several GlcNAc and galactose subunits, and is terminated by sialic acid (Neu5Ac), sulfate (SO3) and fucose. Mucin glycans are always O-linked to a serine or threonine residue on the protein backbone.
Primary mucin glycan degraders in the human gut; these bacteria have been shown to degrade mucin glycans in vitro
| Species | Specialist /generalist | Strain | Type of mucin grown on | Enzymatic activities according to CAZy database | References |
|---|---|---|---|---|---|
|
| Specialist | ATCC BAA-835T | pPGM and human MUC2 | α-Galactosidases (GH27, GH36, GH97 and GH110); | ( |
|
| Generalist | VPI-3452AT (ATCC 43185) | BSM, pPGM | α-Galactosidases (GH27, GH36, GH97 and GH110); | ( |
|
| Generalist | DSM 22519T | pPGM | Not in CAZy | ( |
|
| Generalist | DSM 18011T | pPGM | Not in CAZy | ( |
|
| Generalist | DSM 24798T | pPGM | Not in CAZy | ( |
|
| Generalist | DSM 17565T | pPGM | Not in CAZy | ( |
|
| Generalist | VPI-2393 | BSM | ( | |
| ATCC 25285T (DSM 2151) | PGM, PCM, purified | ATCC 25285: α-galactosidases (GH27, GH36, GH97 and GH110); | ( | ||
|
| Generalist | DSM 18171T | pPGM | Not in CAZy | ( |
|
| Generalist | DSM 20613T | pPGM | α-Galactosidases (GH27, GH36, GH97 and GH110); | ( |
|
| Generalist | DSM 17393T | pPGM | α-Galactosidases (GH27, GH36 and GH97); | ( |
|
| Generalist | DSM 18764T | pPGM | Not in CAZy | ( |
|
| Generalist | DSM 1896T | pPGM | α-Galactosidases (GH27, GH36 and GH97); | ( |
|
| Generalist | DSM 19555T | pPGM | Not in CAZy | ( |
|
| Generalist | ATCC 29148T | Glycans from PGM, pPGM | α-Galactosidases (GH27, GH36, GH97 and GH110); | ( |
|
| Generalist | DSM 6597T | pPGM | Not in CAZy | ( |
|
| Generalist | DSM 18836T (XB1A) | pPGM | α-Galactosidase (GH27, GH36 and GH97); | ( |
|
| Generalist | DSM 17679T | Porcine mucin | Not in CAZy | ( |
|
| Generalist | VIII-271F | ppPGM | ( | |
| ATCC 8482T | pPGM | α-Galactosidase (GH27, GH36, GH97 and GH110); | ( | ||
|
| Specialist | DSM 21032T | pPGM | Not in CAZy | ( |
|
| Specialist | ATCC 35913 | ppPGM and pPGM | ( | |
| ATCC 29149T | pPGM and human MUC2 | α-Galactosidase (GH36); | ( | ||
|
| Specialist | ATCC 35915 | ppPGM | ( | |
| VIII-239 | ppPGM | ( | |||
| ATCC 27756T | pPGM and human MUC2 | ( | |||
|
| Generalist | VIII-210 | ppPGM | ( | |
| 24/25 strains | PGM | ( | |||
| D119 and L22 | PGM | ( | |||
| PRL2010, A8, 324B, 156B, D119 and DSM 20456T (ATCC 29521), 85B (limited growth on mucin) and L22 (limited growth on mucin) | PGM | DSM 20456T: α-galactosidase (GH36, GH110); | ( | ||
|
| Generalist | NCIMB8807 (UCC2003) | PGM | α-Galactosidase (GH36); | ( |
|
| Generalist | VIII-240 | ppPGM | ( | |
| NCTC11817T (ATCC 15697) | α-Galactosidase (GH36); | ||||
|
| Generalist | NCIMB8809 | PGM, HIM | α-Galactosidase (GH27 and GH36); | ( |
BSM, bovine submaxillary mucin; HIM, human intestinal mucin; PGM, purified pig gastric mucin; pPGM, purified pig gastric mucin; ppPGM, partially purified pig gastric mucin.
The consortium of PMDs (PMD consortium)
| Phylum | Verrucomicrobia | Bacteroidetes | Firmicutes | Actinobacteria | Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Species |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| Strain | Activities in this family that are (potentially) involved in mucin glycan degradation (CAZy) | ATCC BAA-835 | DSM 2079 | DSM 2151 | ATCC 8482 | ATCC 43185 | P 36–108 | APC919 / 174 | ATCC 8483 | XB1A | NBRC 113350 | ATCC 29149 | L2-14 | NCIMB8809 | NCTC11817 | UCC2003 | ATCC 29521 | |
| GH2 | β-Galactosidase and exo-β-glucosaminidase | 5 | 31 | 2 | 25 | 17 | 11 | 35 | 37 | 23 | 22 | 5 | 2 | 3 | 3 | 5 | 3 | 229 |
| GH16 | Endo-β1–4-galactosidase | 3 | 3 | 6 | 1 | 7 | 2 | 2 | 4 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 34 |
| GH18 | Endo-β- | 1 | 12 | 2 | 2 | 0 | 4 | 3 | 8 | 8 | 3 | 2 | 1 | 0 | 1 | 1 | 0 | 48 |
| GH20 | β-Hexosaminidase, lacto- | 11 | 14 | 12 | 9 | 12 | 8 | 7 | 13 | 10 | 6 | 0 | 0 | 1 | 3 | 1 | 4 | 111 |
| GH27 | α-Galactosidase | 1 | 5 | 3 | 1 | 1 | 1 | 3 | 3 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 20 |
| GH29 | Fucosidase | 4 | 9 | 8 | 8 | 12 | 6 | 4 | 7 | 4 | 3 | 2 | 0 | 0 | 3 | 0 | 1 | 71 |
| GH33 | Sialidase | 3 | 2 | 4 | 3 | 3 | 3 | 1 | 5 | 4 | 0 | 1 | 0 | 0 | 2 | 1 | 4 | 36 |
| GH35 | β-Galactosidase | 2 | 3 | 4 | 1 | 4 | 1 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 23 |
| GH36 | α-Galactosidase and α- | 3 | 4 | 3 | 3 | 2 | 1 | 4 | 3 | 5 | 2 | 2 | 3 | 2 | 1 | 2 | 1 | 41 |
| GH42 | β-Galactosidase | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 3 | 3 | 2 | 2 | 17 |
| GH84 | β- | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 10 |
| GH85 | Endo-β- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| GH89 | α- | 2 | 3 | 1 | 1 | 3 | 1 | 2 | 4 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 24 |
| GH95 | Fucosidase | 2 | 5 | 4 | 4 | 5 | 1 | 7 | 7 | 4 | 1 | 3 | 2 | 0 | 1 | 1 | 1 | 48 |
| GH97 | α-Galactosidase | 1 | 10 | 4 | 7 | 4 | 2 | 15 | 12 | 6 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 74 |
| GH98 | Blood group endo-β1–4-galactosidase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| GH101 | Endo-α- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| GH109 | α- | 2 | 2 | 2 | 5 | 4 | 2 | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 24 |
| GH110 | α-Galactosidase | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 12 |
| GH129 | α- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 |
| Total | 43 | 107 | 58 | 74 | 77 | 46 | 88 | 109 | 74 | 61 | 17 | 8 | 13 | 18 | 16 | 23 | ||
Note: CAZyme families involved in mucin glycan degradation and their distribution over mucin glycan degraders (Martens et al. 2008; Tailford, Crost, et al. 2015; Desai et al. 2016; Kosciow and Deppenmeier 2019; Crouch et al. 2020; Pruss et al. 2021). For each mucin glycan degrader, the number of GHs per family are indicated, as listed in the CAZy database (Lombard et al. 2014).
aNot the type strain, but only strain included in CAZy, no in vitro proof that this strain degrades mucin glycans.
Fig. 2Functional distribution of GHs implicated in mucin glycan degradation in a consortium of primary mucin glycan degraders (the PMD consortium, Table II). (A) Number of genes encoding GH family members that are implicated in mucin glycan degradation in the PMD consortium of mucin glycan degraders that are included in the CAZy database. (B) Number of genes within the PMD consortium encoding GH family members grouped by their function. Two families (GH2 and GH36) comprise both galactosidases and hexosaminidases and are therefore shown separately.
Fig. 3A hypothetical mucin glycan and the enzyme classes that are required to hydrolyze the bonds between the subunits.
Cocultivations that cooperatively break down mucin glycans
| Mucin degrader | Partner(s) | Method | Metabolites and gases exchanged | Reference |
|---|---|---|---|---|
|
|
| Coculture on PGM |
| ( |
|
|
| Cocolonization of GF mice |
| ( |
|
|
| Cocolonization of GF rats |
| ( |
|
|
| Coculture on chondroitin sulfate and cocolonization of GF mice |
| ( |
|
|
| Coculture on PGM |
| ( |
|
|
| Coculture on PGM |
| ( |
|
|
| Coculture on PGM | Cocultivation of | ( |
|
|
| Coculture on PGM |
| ( |
|
|
| Coculture on PCM |
| ( |
|
|
| Coculture on a mucin mixture |
| ( |
Fig. 4Cooperative mucin glycan degradation of a mucin glycan degrader and a butyrate-producing partner organism results in the production of SCFAs. Extracellular CAZymes of the mucin glycan degrader release shorter glycans from mucin. These glycans are imported into the cell, where further degradation takes place. This results in the production of SCFAs propionate and acetate. Subsequently, acetate can be taken up by a partner organism, which produces butyrate from acetate. Butyrate is secreted and becomes available to the host.
Fig. 5Cross-feeding of Bifidobacterium spp. with butyrate producer A. hallii: A three-species mucin coculture of B. bifidum, B. breve or B. infantis and A. hallii produces SCFAs propionate and butyrate. Mucin glycan degradation by B. bifidum releases fucose, acetate and lactate. B. infantis or B. breve can use fucose to produce acetate, lactate and 1,2-propanediol. A. hallii uses 1,2-propanediol to produce propionate and uses acetate and lactate to produce butyrate (Bunesova et al. 2018).